JP5461712B2 - N−(ブロモアセチル)−3,3−ジニトロアゼチジンの合成及び単離法並びにそれを含む組成物 - Google Patents
N−(ブロモアセチル)−3,3−ジニトロアゼチジンの合成及び単離法並びにそれを含む組成物 Download PDFInfo
- Publication number
- JP5461712B2 JP5461712B2 JP2012552884A JP2012552884A JP5461712B2 JP 5461712 B2 JP5461712 B2 JP 5461712B2 JP 2012552884 A JP2012552884 A JP 2012552884A JP 2012552884 A JP2012552884 A JP 2012552884A JP 5461712 B2 JP5461712 B2 JP 5461712B2
- Authority
- JP
- Japan
- Prior art keywords
- abdnaz
- solvent
- dnaz
- dichloromethane
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- JODKFOVZURLVTG-UHFFFAOYSA-N 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone Chemical compound [O-][N+](=O)C1([N+]([O-])=O)CN(C(=O)CBr)C1 JODKFOVZURLVTG-UHFFFAOYSA-N 0.000 title claims description 179
- 238000000034 method Methods 0.000 title claims description 61
- 239000000203 mixture Substances 0.000 title claims description 11
- 230000002194 synthesizing effect Effects 0.000 title description 4
- 239000002904 solvent Substances 0.000 claims description 130
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 129
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 99
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 55
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 54
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 claims description 40
- 239000011541 reaction mixture Substances 0.000 claims description 33
- LSTRKXWIZZZYAS-UHFFFAOYSA-N 2-bromoacetyl bromide Chemical compound BrCC(Br)=O LSTRKXWIZZZYAS-UHFFFAOYSA-N 0.000 claims description 23
- 239000008346 aqueous phase Substances 0.000 claims description 20
- 239000012074 organic phase Substances 0.000 claims description 18
- 238000006243 chemical reaction Methods 0.000 claims description 15
- 239000000725 suspension Substances 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 10
- 239000002274 desiccant Substances 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 8
- 238000005406 washing Methods 0.000 claims description 8
- 238000001704 evaporation Methods 0.000 claims description 7
- 238000010992 reflux Methods 0.000 claims description 7
- 239000011877 solvent mixture Substances 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 5
- YNVDAIOEJHCEQA-UHFFFAOYSA-N 1-tert-butyl-3,3-dinitroazetidine Chemical compound CC(C)(C)N1CC([N+]([O-])=O)([N+]([O-])=O)C1 YNVDAIOEJHCEQA-UHFFFAOYSA-N 0.000 claims description 4
- 239000013078 crystal Substances 0.000 claims description 4
- WBJINCZRORDGAQ-UHFFFAOYSA-N ethyl formate Chemical compound CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 claims description 4
- 238000011084 recovery Methods 0.000 claims description 3
- 239000000243 solution Substances 0.000 description 71
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 61
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 51
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 24
- 238000006396 nitration reaction Methods 0.000 description 18
- 230000001590 oxidative effect Effects 0.000 description 18
- 230000015572 biosynthetic process Effects 0.000 description 17
- 239000007787 solid Substances 0.000 description 14
- 238000003786 synthesis reaction Methods 0.000 description 14
- -1 Cyclic nitro compounds Chemical class 0.000 description 13
- 238000002955 isolation Methods 0.000 description 12
- 235000010288 sodium nitrite Nutrition 0.000 description 12
- FMXOEQQPVONPBU-UHFFFAOYSA-N methylidene(dioxido)azanium Chemical class [O-][N+]([O-])=C FMXOEQQPVONPBU-UHFFFAOYSA-N 0.000 description 11
- 238000000605 extraction Methods 0.000 description 10
- 238000003756 stirring Methods 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 239000006227 byproduct Substances 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 239000012535 impurity Substances 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- 239000003960 organic solvent Substances 0.000 description 7
- LCPVQAHEFVXVKT-UHFFFAOYSA-N 2-(2,4-difluorophenoxy)pyridin-3-amine Chemical compound NC1=CC=CN=C1OC1=CC=C(F)C=C1F LCPVQAHEFVXVKT-UHFFFAOYSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 238000002425 crystallisation Methods 0.000 description 6
- 230000008025 crystallization Effects 0.000 description 6
- 230000008020 evaporation Effects 0.000 description 6
- CHQMHPLRPQMAMX-UHFFFAOYSA-L sodium persulfate Substances [Na+].[Na+].[O-]S(=O)(=O)OOS([O-])(=O)=O CHQMHPLRPQMAMX-UHFFFAOYSA-L 0.000 description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 description 6
- 235000011152 sodium sulphate Nutrition 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000002360 explosive Substances 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 230000002051 biphasic effect Effects 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 238000003828 vacuum filtration Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- ZLYKMXLCTFBEGU-UHFFFAOYSA-N (1-tert-butyl-3-nitroazetidin-3-yl)methanol Chemical compound CC(C)(C)N1CC(CO)([N+]([O-])=O)C1 ZLYKMXLCTFBEGU-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000006057 Non-nutritive feed additive Substances 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 238000010420 art technique Methods 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- HHCCNQLNWSZWDH-UHFFFAOYSA-N n-hydroxymethanimine oxide Chemical compound O[N+]([O-])=C HHCCNQLNWSZWDH-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011112 process operation Methods 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 238000009781 safety test method Methods 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Description
本願は、2010年2月9日出願の米国特許出願第12/702,782号“N−(ブロモアセチル)−3,3−ジニトロアゼチジンの合成及び単離法並びにそれを含む組成物(METHODS OF SYNTHESIZING AND ISOLATING N-(BROMOACETYL)-3,3-DINITROAZETIDINE AND A COMPOSITION INCLUDING THE SAME)”の出願日の利益を主張する。
本明細書は、本発明と見なされることを特に指摘し、明確に主張している特許請求の範囲で締め括られているが、本発明の利点は、以下の本発明の説明を添付の図面と併せて読むことにより、より容易に確認できるであろう。
HMNAZからDNAZの合成
磁気撹拌棒を備えた三角フラスコに、水(400mL)、フェリシアン化カリウム(17.2g、52mmol)、及び亜硝酸ナトリウム(143.2g、2075mmol)を装入した。該溶液(本明細書中では“溶液A”と呼ぶ)を全固体が溶解するまで撹拌した(約15分)。
DNAZからABDNAZの合成
磁気撹拌棒及びウォーター・ジャケット付き還流冷却器を備えた三口丸底フラスコ(3L)に、DNAZのジクロロメタン溶液(実施例1に記載のように製造)を装入した。装置の窒素ガスパージを開始し、10分後、三フッ化ホウ素ジエチルエーテラート(6.37mL、52mmol)を加え、次いでブロモアセチルブロミド(33.77mL、388mmol)を加えた。冷却器頂部の小通気口を除いてフラスコを密封し、溶液を加熱して穏やかに還流した。6時間(±0.5時間)後、加熱を中止し、ジクロロメタン(1000mL)及び蒸留水(80mL)をこの順に不均一混合物に加えた。この二相系を全固体(DNAZ HBr)が溶解するまで16時間激しく撹拌した。次に、この二相系を分液漏斗に移した。水性相を除去し、有機相を追加の蒸留水で洗浄した(4×500mL)。有機層を硫酸ナトリウム(100g〜150g)で乾燥させた後、一口丸底フラスコに移した。該溶液を回転蒸発器上でその初期体積の約半分に濃縮した後、エタノール(250mL)を加えた。残りのジクロロメタンを回転蒸発器によって除去すると、透明の無色結晶の沈殿が起きた。フラスコを氷浴で30分間冷却した。沈殿物を減圧ろ過によって単離し、追加の冷エタノールで濯ぎ(5×150mL)、乾燥させて純粋なABDNAZを得た(56.04g、収率81%)。
表1に、本発明の方法によって製造されたABDNAZの2個のサンプルと、ベドナルスキー法によって製造されたABDNAZの性質をリストアップする。
Claims (17)
- N−(ブロモアセチル)−3,3−ジニトロアゼチジン(ABDNAZ)の製造法であって、
1−tert−ブチル−3,3−ジニトロアゼチジン(DNAZ)を溶媒中でブロモアセチルブロミド及び三フッ化ホウ素エーテラートと反応させて、ABDNAZ及びDNAZの塩を含む反応混合物を製造し;
水及び追加量の溶媒を反応混合物に加えて、ABDNAZを含む有機相とDNAZの塩を含む水性相を形成させ;
有機相と水性相を分離して、ABDNAZを含むABDNAZ/溶媒溶液と、DNAZの塩を含む水性相を製造し;
非溶媒をABDNAZ/溶媒溶液に加えて、ABDNAZ/溶媒/非溶媒混合物を製造し;そして
ABDNAZを回収する
ことを含む方法。 - DNAZを溶媒中でブロモアセチルブロミド及び三フッ化ホウ素エーテラートと反応させてABDNAZ及びDNAZの塩を含む反応混合物を製造することが、DNAZ、ブロモアセチルブロミド、及び三フッ化ホウ素エーテラートを還流で約4時間〜約7時間の間反応させることを含む、請求項1に記載の方法。
- DNAZを溶媒中でブロモアセチルブロミド及び三フッ化ホウ素エーテラートと反応させてABDNAZ及びDNAZの塩を含む反応混合物を製造することが、DNAZをブロモアセチルブロミド及び三フッ化ホウ素エーテラートとジクロロメタン中で反応させることを含む、請求項1に記載の方法。
- DNAZを溶媒中でブロモアセチルブロミド及び三フッ化ホウ素エーテラートと反応させることが、2モル当量のDNAZをジクロロメタン中で1.5モル当量のブロモアセチルブロミドと反応させることを含む、請求項1に記載の方法。
- 水及び追加量の溶媒を反応混合物に加えて有機相と水性相を形成させることが、ジクロロメタン及び水を反応混合物に添加することを含む、請求項1に記載の方法。
- 非溶媒を加える前に、ABDNAZ/溶媒溶液を水で洗浄することをさらに含む、請求項1に記載の方法。
- 水を除去するために乾燥剤をABDNAZ/溶媒溶液に加え、そして乾燥剤を回収することをさらに含む、請求項6に記載の方法。
- ABDNAZ/溶媒溶液から溶媒の少なくとも一部分を除去することをさらに含む、請求項7に記載の方法。
- 非溶媒をABDNAZ/溶媒溶液に加えることが、エタノールをABDNAZ/溶媒溶液に加えることを含む、請求項1に記載の方法。
- ABDNAZの回収が、ABDNAZ/溶媒/非溶媒混合物から溶媒を除去することを含む、請求項1に記載の方法。
- ABDNAZの回収が、非溶媒を除去してABDNAZの結晶を製造することを含む、請求項1に記載の方法。
- N−(ブロモアセチル)−3,3−ジニトロアゼチジン(ABDNAZ)の製造法であって、
1−tert−ブチル−3,3−ジニトロアゼチジン(DNAZ)をジクロロメタン中でブロモアセチルブロミド及び三フッ化ホウ素エーテラートと反応させて、ABDNAZ及びDNAZの臭化水素塩を含む反応混合物を製造し;
水及び追加量のジクロロメタンを反応混合物に加えて、ジクロロメタン及びABDNAZを含む有機相と水及びDNAZの臭化水素塩を含む水性相を形成させ;
有機相を水性相から分離し;
エタノールをジクロロメタン及びABDNAZを含む有機相に加え;
減圧下でジクロロメタンを蒸発させてABDNAZ/エタノール懸濁液を形成させ;そして
ABDNAZ/エタノール懸濁液からエタノールをろ過する
ことを含む方法。 - ABDNAZ/エタノール懸濁液からのエタノールのろ過が、HMNAZからDNAZの推定100%収率を基にして、約80%〜約100%の収率でABDNAZを製造することを含む、請求項12に記載の方法。
- ABDNAZ/エタノール懸濁液からのエタノールのろ過が、約99.5%より高い純度を有するABDNAZを製造することを含む、請求項12に記載の方法。
- 約99.5%より高い純度のN−(ブロモアセチル)−3,3−ジニトロアゼチジン(ABDNAZ)及び製薬学的に有効なビヒクルを含み、1−tert−ブチル−3,3−ジニトロアゼチジンの塩を実質的に含まない組成物。
- 組成物が、約0.4%未満の1−tert−ブチル−3,3−ジニトロアゼチジンしか含まない、請求項15に記載の組成物。
- 組成物が、ブロモ酢酸を実質的に含まない、請求項15に記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/702,782 | 2010-02-09 | ||
US12/702,782 US8471041B2 (en) | 2010-02-09 | 2010-02-09 | Methods of synthesizing and isolating N-(bromoacetyl)-3,3-dinitroazetidine and a composition including the same |
PCT/US2011/021500 WO2011100090A1 (en) | 2010-02-09 | 2011-01-18 | Methods of synthesizing and isolating n-(bromoacetyl)-3,3-dinitroazetidine and a composition including the same |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2013518925A JP2013518925A (ja) | 2013-05-23 |
JP2013518925A5 JP2013518925A5 (ja) | 2013-08-29 |
JP5461712B2 true JP5461712B2 (ja) | 2014-04-02 |
Family
ID=43875262
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012552884A Active JP5461712B2 (ja) | 2010-02-09 | 2011-01-18 | N−(ブロモアセチル)−3,3−ジニトロアゼチジンの合成及び単離法並びにそれを含む組成物 |
Country Status (12)
Country | Link |
---|---|
US (1) | US8471041B2 (ja) |
EP (1) | EP2534131B1 (ja) |
JP (1) | JP5461712B2 (ja) |
KR (1) | KR101456438B1 (ja) |
CN (1) | CN102762535B (ja) |
AU (1) | AU2011216176B2 (ja) |
CA (1) | CA2788459C (ja) |
DK (1) | DK2534131T3 (ja) |
ES (1) | ES2460040T3 (ja) |
IL (1) | IL221141A (ja) |
MX (1) | MX2012008989A (ja) |
WO (1) | WO2011100090A1 (ja) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7507842B2 (en) | 2005-08-12 | 2009-03-24 | Radiorx, Inc. | Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof |
US20070135380A1 (en) | 2005-08-12 | 2007-06-14 | Radiorx, Inc. | O-nitro compounds, pharmaceutical compositions thereof and uses thereof |
US8664247B2 (en) | 2011-08-26 | 2014-03-04 | Radiorx, Inc. | Acyclic organonitro compounds for use in treating cancer |
WO2013052164A1 (en) | 2011-10-07 | 2013-04-11 | Radiorx, Inc. | Organonitro thioether compounds and medical uses thereof |
US20140308260A1 (en) | 2011-10-07 | 2014-10-16 | Radiorx, Inc. | Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products |
US10342778B1 (en) | 2015-10-20 | 2019-07-09 | Epicentrx, Inc. | Treatment of brain metastases using organonitro compound combination therapy |
US9987270B1 (en) | 2015-10-29 | 2018-06-05 | Epicentrix, Inc. | Treatment of gliomas using organonitro compound combination therapy |
DK3402480T3 (da) | 2016-01-11 | 2021-06-28 | Epicentrx Inc | Sammensætninger og fremgangsmåder til intravenøs administration af 2-brom-1-(3,3-dinitroazetidin-1-yl)ethanon |
CN110352190A (zh) | 2016-10-14 | 2019-10-18 | 埃皮辛特瑞柯斯公司 | 用于医疗用途的磺氧基烷基有机硝基和相关化合物和药物组合物 |
EP3648740A1 (en) | 2017-07-07 | 2020-05-13 | EpicentRx, Inc. | Compositions for parenteral administration of therapeutic agents |
US11510901B2 (en) | 2018-01-08 | 2022-11-29 | Epicentrx, Inc. | Methods and compositions utilizing RRx-001 combination therapy for radioprotection |
WO2022261284A1 (en) * | 2021-06-09 | 2022-12-15 | Epicentrx, Inc. | Crystalline abdnaz compositions and methods of making and using the same |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4935450A (en) | 1982-09-17 | 1990-06-19 | Therapeutical Systems Corporation | Cancer therapy system for effecting oncolysis of malignant neoplasms |
JPS60116642A (ja) | 1983-11-29 | 1985-06-24 | Nippon Kayaku Co Ltd | 2−モノ−置換メチル−5,5−ジメチル−シクロ−2−ヘキセノン誘導体 |
GB8504253D0 (en) * | 1985-02-19 | 1985-03-20 | Ici Plc | Electrostatic spraying apparatus |
GB8728418D0 (en) * | 1987-12-04 | 1988-01-13 | Jenkins T C | Nitro-substituted aromatic/hetero-aromatic compounds for use in cancer treatment |
DE3815221C2 (de) * | 1988-05-04 | 1995-06-29 | Gradinger F Hermes Pharma | Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen |
US5693794A (en) * | 1988-09-30 | 1997-12-02 | The United States Of America As Represented By The Secretary Of The Navy | Caged polynitramine compound |
JP2659614B2 (ja) * | 1990-11-13 | 1997-09-30 | 株式会社日立製作所 | 表示制御装置 |
US5698155A (en) * | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
US5336784A (en) * | 1993-06-07 | 1994-08-09 | The Regents Of The University Of California | Synthesis of 1,3,3-trinitroazetidine |
ES2092460T3 (es) | 1994-05-27 | 2001-02-01 | Cellegy Pharma Inc | Composicion dadora de oxido nitrico para el tratamiento de trastornos anales. |
JP3585127B2 (ja) * | 1995-03-14 | 2004-11-04 | シーメンス アクチエンゲゼルシヤフト | 超音波噴霧システム |
AU701843B2 (en) * | 1995-03-14 | 1999-02-04 | Siemens Aktiengesellschaft | Removable precision dosating unit for ultrasonic atomizer device |
AU5798996A (en) | 1995-05-15 | 1996-11-29 | Sachs, Michael C. | Adnaz, compositions and processes |
US5580988A (en) * | 1995-05-15 | 1996-12-03 | The United States Of America As Represented By The Secretary Of The Army | Substituted azetidines and processes of using them |
US5898038A (en) * | 1996-03-19 | 1999-04-27 | Board Of Regents, The University Of Texas System | Treatment of osteoporosis and metabolic bone disorders with nitric oxide substrate and/or donors |
AU3129097A (en) | 1996-10-15 | 1998-05-11 | Eastman Chemical Company | Explosive formulations |
GB9720797D0 (en) | 1997-09-30 | 1997-12-03 | Rhodes John | Pharmaceutical composition for the treatment of inflammatory bowel disease and irritable bowel syndrome |
NZ504021A (en) * | 1997-10-17 | 2003-04-29 | Systemic Pulmonary Delivery Lt | Method and apparatus for delivering aerosolized medication having air discharged through air tube directly into plume of aerosolized medication |
US6056966A (en) * | 1998-05-18 | 2000-05-02 | Baker Norton Pharmaceuticals, Inc. | Method and compositions for treating impotence |
US7635722B1 (en) | 1998-07-27 | 2009-12-22 | Saint Jude Pharmaceuticals, Inc. | Chemical induced intracellular hyperthermia |
US6448253B1 (en) * | 1998-09-16 | 2002-09-10 | King Pharmaceuticals Research And Development, Inc. | Adenosine A3 receptor modulators |
US6245799B1 (en) * | 1999-11-08 | 2001-06-12 | American Home Products Corp | [(Indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders |
YU73902A (sh) | 2000-04-10 | 2005-09-19 | Pfizer Products Inc. | Jedinjenja koja sadrže benzoamid-piperidin i srodna jedinjenja |
US6861530B2 (en) * | 2000-07-07 | 2005-03-01 | Kyowa Hakko Kogyo Co., Ltd. | Piperidine derivatives |
DE10111049A1 (de) | 2001-03-06 | 2002-09-12 | Beiersdorf Ag | Verwendung von Substanzen, die verhindern, daß die NO-Synthese des warmblütigen Organismus ihre Wirkung entfaltet, zur Herstellung von kosmetischen oder dermatologischen Zubereitungen, zur Prophylaxe und Behandlung von entzündlichen Hautzuständen und/oder zum Hautschutz bei empfindlich determinierter trockener Haut |
EP1336602A1 (en) | 2002-02-13 | 2003-08-20 | Giovanni Scaramuzzino | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases |
WO2004004648A2 (en) * | 2002-07-03 | 2004-01-15 | Nitromed, Inc. | Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use |
US20040167212A1 (en) * | 2002-10-07 | 2004-08-26 | Bednarski Mark D. | X-nitro compounds, pharmaceutical compositions thereof and uses thereof |
US6870061B2 (en) * | 2003-01-10 | 2005-03-22 | Alliant Techsystems Inc. | Continuous process and system for production of glycidyl nitrate from glycerin, nitric acid and caustic and conversion of glycidyl nitrate to poly(glycidyl nitrate) |
CA2518506A1 (en) | 2003-03-13 | 2004-11-18 | Nitromed, Inc. | Nitrosated and nitrosylated compounds, compositions and methods of use |
RU2326864C2 (ru) | 2003-06-25 | 2008-06-20 | Дзе Ил Фармасьютикал Ко., Лтд. | Трициклические производные или их фармацевтически приемлемые соли, способы их получения и содержащие их фармацевтические композиции |
GB0326047D0 (en) | 2003-11-07 | 2003-12-10 | Univ Sheffield | Substance |
WO2006029385A2 (en) * | 2004-09-08 | 2006-03-16 | Chelsea Therapeutics, Inc. | Quinazoline derivatives as metabolically inert antifolate compounds. |
US7507842B2 (en) * | 2005-08-12 | 2009-03-24 | Radiorx, Inc. | Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof |
US20070135380A1 (en) | 2005-08-12 | 2007-06-14 | Radiorx, Inc. | O-nitro compounds, pharmaceutical compositions thereof and uses thereof |
JP2009510073A (ja) * | 2005-09-27 | 2009-03-12 | ノバルティス アクチエンゲゼルシャフト | カルボキシアミン化合物およびその使用方法 |
KR100967848B1 (ko) * | 2008-05-28 | 2010-07-05 | 국방과학연구소 | 분자화약이 도입된, 고에너지 결합제용1-글리시딜-3,3-디니트로아제티딘 및 그의 제조방법 |
US20120149678A1 (en) * | 2010-12-09 | 2012-06-14 | Oronsky Bryan T | Organonitro Compounds for Use in Treating Non-Hodgkin's Lymphoma and Leukemia, and Methods Relating Thereto |
-
2010
- 2010-02-09 US US12/702,782 patent/US8471041B2/en active Active
-
2011
- 2011-01-18 KR KR1020127022598A patent/KR101456438B1/ko active IP Right Grant
- 2011-01-18 WO PCT/US2011/021500 patent/WO2011100090A1/en active Application Filing
- 2011-01-18 JP JP2012552884A patent/JP5461712B2/ja active Active
- 2011-01-18 AU AU2011216176A patent/AU2011216176B2/en active Active
- 2011-01-18 CA CA2788459A patent/CA2788459C/en active Active
- 2011-01-18 DK DK11700989.4T patent/DK2534131T3/da active
- 2011-01-18 EP EP11700989.4A patent/EP2534131B1/en active Active
- 2011-01-18 CN CN201180008968.3A patent/CN102762535B/zh active Active
- 2011-01-18 MX MX2012008989A patent/MX2012008989A/es active IP Right Grant
- 2011-01-18 ES ES11700989.4T patent/ES2460040T3/es active Active
-
2012
- 2012-07-26 IL IL221141A patent/IL221141A/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
IL221141A0 (en) | 2012-09-24 |
US8471041B2 (en) | 2013-06-25 |
MX2012008989A (es) | 2012-08-23 |
JP2013518925A (ja) | 2013-05-23 |
EP2534131A1 (en) | 2012-12-19 |
IL221141A (en) | 2016-08-31 |
AU2011216176A1 (en) | 2012-08-23 |
KR20130053385A (ko) | 2013-05-23 |
CA2788459A1 (en) | 2011-08-18 |
CN102762535A (zh) | 2012-10-31 |
KR101456438B1 (ko) | 2014-10-31 |
CA2788459C (en) | 2016-01-05 |
EP2534131B1 (en) | 2014-03-19 |
CN102762535B (zh) | 2014-09-03 |
US20110195947A1 (en) | 2011-08-11 |
WO2011100090A1 (en) | 2011-08-18 |
AU2011216176B2 (en) | 2013-11-14 |
DK2534131T3 (da) | 2014-04-07 |
ES2460040T3 (es) | 2014-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5461712B2 (ja) | N−(ブロモアセチル)−3,3−ジニトロアゼチジンの合成及び単離法並びにそれを含む組成物 | |
JP2008516005A (ja) | レトロゾールの改良された調製方法 | |
EP2906530B1 (en) | Processes for the synthesis of 2-amino-4,6-dimethoxybenzamide and other benzamide compounds | |
JP2004504319A (ja) | 4−フェニルピペリジン誘導体の新規製造方法 | |
US8461347B2 (en) | Process for preparing form A of atazanavir sulfate | |
JP2011006379A (ja) | {2−アミノ−1,4−ジヒドロ−6−メチル−4−(3−ニトロフェニル)−3,5−ピリジンジカルボン酸3−(1−ジフェニルメチルアゼチジン−3−イル)エステル5−イソプロピルエステル}(アゼルニジピン)の再結晶方法、アゼルニジピンのイソプロピルアルコール付加体、およびアゼルニジピンの製造方法 | |
JP5643844B2 (ja) | トピラマート(topiramate)の製造方法 | |
JP4425906B2 (ja) | 4−ヒドロキシカルバモイルフェニル)−カルバミン酸(6−ジエチルアミノメチル−ナフタレン−2−イル)エステルの塩酸一水和物 | |
JP6816274B2 (ja) | (s)−n1−(2−アミノエチル)−3−(4−アルコキシフェニル)プロパン−1,2−ジアミン三塩酸塩の製造方法 | |
JP2013544768A (ja) | ビカルタミドの調製方法 | |
US8952148B2 (en) | Process for the preparation of taurolidine and its intermediates thereof | |
JP4833419B2 (ja) | 環式酸の製造 | |
CN101654426B (zh) | 制备伊洛马司他的方法 | |
JP5192730B2 (ja) | メルカプト複素環化合物の製造方法 | |
JPH0597782A (ja) | 塩酸ベバントロールの製造方法 | |
JP4397990B2 (ja) | 3−アルキルフラバノノール誘導体の精製法 | |
KR101622630B1 (ko) | 디클로페낙 콜린 염의 합성 방법 | |
JP3230723B2 (ja) | 2−(フルフリルチオ)酢酸誘導体の製造方法 | |
JP5836851B2 (ja) | ブリンゾラミドの製造方法 | |
WO2023100110A1 (en) | Process for preparing brivaracetam | |
JP2815438B2 (ja) | 1,2―ビス(ニコチンアミド)プロパンの精製方法 | |
JPH06345735A (ja) | N−置換−3−ピペリジノールの製法 | |
WO2006059774A1 (ja) | ジアリルビスフェノール化合物の精製方法 | |
JP4052786B2 (ja) | 2−クロロ−4−(1−ピペリジニルメチル)ピリジンの精製方法 | |
CN113461709A (zh) | 喷沙西林氢碘酸盐的合成方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130709 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130709 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20130709 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20130805 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130828 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20131217 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140115 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5461712 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |